Over the past five years, the Brand Name Pharmaceutical Manufacturing industry has grappled with generating sales volumes, thanks to many provinces and territories implementing incentives to bolster generic drug utilization rates. As the cost discrepancy between generic and brand-name drugs has risen, many public and private payers have aimed to bolster generic drug use, intensifying competition for the industry. Still, industry revenue is expected to increase over the past five years, which can be attributed to robust demand for biologic drugs. Over the next five years, the industry is expected to exhibit growth, driven by increasing demand for biologics from an aging population. However, the industry will still contend with strong competition from generic drug makers.
This industry develops prescription and over-the-counter products used to treat illnesses in humans and animals. Brand-name drugs have patent protection. This industry does not include nutritional supplement or cosmetics manufacturers.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.